159 related articles for article (PubMed ID: 9265351)
1. [Criteria for assessing the efficacy of brachytherapy of uveal melanomas, complications of therapy and there prevention].
Brovkina AF; Zarubeí GD; Val'skií VV
Vestn Oftalmol; 1997; 113(3):14-6. PubMed ID: 9265351
[TBL] [Abstract][Full Text] [Related]
2. Ocular complications after iodine brachytherapy for large uveal melanomas.
Puusaari I; Heikkonen J; Kivelä T
Ophthalmology; 2004 Sep; 111(9):1768-77. PubMed ID: 15350335
[TBL] [Abstract][Full Text] [Related]
3. [Long-term results of cobalt 60 curietherapy for uveal melanoma].
Bacin F; Kwiatkowski F; Dalens H; Rozan R; Gagyi S; Donnarieix D; Bard JJ; Robert JL
J Fr Ophtalmol; 1998 May; 21(5):333-44. PubMed ID: 9759427
[TBL] [Abstract][Full Text] [Related]
4. Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques.
Puusaari I; Heikkonen J; Kivelä T
Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3425-34. PubMed ID: 15452045
[TBL] [Abstract][Full Text] [Related]
5. Pigmented episcleral deposits after brachytherapy of uveal melanoma.
Toivonen P; Kivelä T
Ophthalmology; 2006 May; 113(5):865-73. PubMed ID: 16530837
[TBL] [Abstract][Full Text] [Related]
6. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays).
Rouberol F; Roy P; Kodjikian L; Gérard JP; Jean-Louis B; Grange JD
Am J Ophthalmol; 2004 May; 137(5):893-900. PubMed ID: 15126155
[TBL] [Abstract][Full Text] [Related]
7. 18 years' experience with high dose rate strontium-90 brachytherapy of small to medium sized posterior uveal melanoma.
van Ginderdeuren R; van Limbergen E; Spileers W
Br J Ophthalmol; 2005 Oct; 89(10):1306-10. PubMed ID: 16170122
[TBL] [Abstract][Full Text] [Related]
8. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S
Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063
[TBL] [Abstract][Full Text] [Related]
9. Ruthenium plaque radiation therapy for iris and iridociliary melanomas.
Razzaq L; Keunen JE; Schalij-Delfos NE; Creutzberg CL; Ketelaars M; de Keizer RJ
Acta Ophthalmol; 2012 May; 90(3):291-6. PubMed ID: 20670343
[TBL] [Abstract][Full Text] [Related]
10. Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation.
Krohn J; Monge OR; Skorpen TN; Mørk SJ; Dahl O
Eye (Lond); 2008 Nov; 22(11):1398-403. PubMed ID: 17585309
[TBL] [Abstract][Full Text] [Related]
11. [Validation of the use of brachytherapy in uveal melanomas of juxtapapillary localization].
Brovkina AF; Zarubeĭ GD; Fishkin IuG
Vestn Oftalmol; 1991; 107(6):41-4. PubMed ID: 1781123
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of malignant melanomas of the uvea with 106-ruthenium applicators. Report on the first 100 Essen cases].
Foerster MH; Bornfeld N; Wessing A; Schulz U; Schmitt G; Meyer-Schwickerath G
Klin Monbl Augenheilkd; 1984 Dec; 185(6):490-4. PubMed ID: 6527503
[TBL] [Abstract][Full Text] [Related]
13. Iris and anterior chamber angle neovascularization after iodine 125 brachytherapy for uveal melanoma.
Detorakis ET; Engstrom RE; Wallace R; Straatsma BR
Ophthalmology; 2005 Mar; 112(3):505-10. PubMed ID: 15745782
[TBL] [Abstract][Full Text] [Related]
14. Disease control and toxicity outcomes using ruthenium eye plaque brachytherapy in the treatment of uveal melanoma.
Takiar V; Gombos DS; Mourtada F; Rechner LA; Lawyer AA; Morrison WH; Garden AS; Beadle BM
Pract Radiat Oncol; 2014; 4(4):e189-94. PubMed ID: 25012839
[TBL] [Abstract][Full Text] [Related]
15. [Motility disorders in brachytherapy of choroid melanomas with Ru106 applicators].
Langmann A; Langmann G; Unlücerci C; Haller E
Ophthalmologe; 1995 Feb; 92(1):76-8. PubMed ID: 7719082
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of conjunctival epithelial tumors: brachytherapy with ruthenium-106].
Buc D; Pilon F; Donnarieix D; Kemeny JL; Bacin F; Rigal D
J Fr Ophtalmol; 2003 Nov; 26(9):929-39. PubMed ID: 14631277
[TBL] [Abstract][Full Text] [Related]
17. Possible effects of radiobiological parameters on metastatic spread of uveal melanomas treated with 106Ru plaques.
Kleineidam M; Guthoff R
Ger J Ophthalmol; 1994 Jan; 3(1):22-5; discussion 25-6. PubMed ID: 8142877
[TBL] [Abstract][Full Text] [Related]
18. Predicting local control of choroidal melanomas following ¹⁰⁶Ru plaque brachytherapy.
Papageorgiou KI; Cohen VM; Bunce C; Kinsella M; Hungerford JL
Br J Ophthalmol; 2011 Feb; 95(2):166-70. PubMed ID: 20889528
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of 100 melanomas of the choroid and ciliary body treated by application of ruthenium (RU 106 Rh 106)].
Grange JD; Gerard JP; Ragab M; Quintero P; Delaroche G; Jean-Louis B; Sentenac I; Fontaniere B; Bievelez B
Bull Soc Ophtalmol Fr; 1989 May; 89(5):679-82. PubMed ID: 2590984
[TBL] [Abstract][Full Text] [Related]
20. A histologic study (including DNA quantification and Ki-67 labeling index) in uveal melanomas after brachytherapy with ruthenium plaques.
Schilling H; Sehu KW; Lee WR
Invest Ophthalmol Vis Sci; 1997 Sep; 38(10):2081-92. PubMed ID: 9331272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
